China Business Information Network: Biopharmaceuticals refers to the use of research results of microbiology, biology, medicine, biochemistry, etc., from organisms, biological tissues, cells, organs, body fluids, etc. A type of products for prevention, treatment and diagnosis are made using scientific principles and methods such as microbiology, chemistry, biochemistry, , biotechnology, pharmacy and other scientific principles and methods.
Upstream industries of biopharmaceuticals mainly involve raw and auxiliary materials production enterprises such as yeast powder, glucose, organic compounds, and inorganic salts, as well as biotechnology research enterprises such as genetic engineering, enzyme engineering, , cell engineering, and fermentation engineering. The downstream industries are hospitals and pharmaceutical retail enterprises. The sales model of biopharmaceutical products is mainly professional academic promotion, and logistics and distribution is carried out through pharmaceutical dealers. Drug manufacturers have the autonomy in the choice of dealers and do not have significant dependence on a certain dealer.
Image source: compiled by China Business Industry Research Institute
The biopharmaceutical industry is a technology-intensive and innovation-driven industry. Many countries have made the biopharmaceutical industry a strategic industry for key development. The biopharmaceutical market has a strong development momentum and broad prospects, and is encouraged and supported by national industrial policies.
Technical characteristics of the biopharmaceutical industry
Compared with traditional chemical pharmaceutical processes, biopharmaceuticals use modern biotechnology means such as genetic engineering, genetic engineering, cellular engineering, and enzyme engineering. The production process is complex, involving the construction of genetically engineered cells or strains, industrial amplification of high-density and high-expression fermentation processes, separation and purification of recombinant proteins, etc., which have high requirements for the professional level of equipment, instruments and technical personnel, and the production process needs to be closely monitored.
In addition, biological drugs are mostly macromolecular drugs such as polypeptide , proteins, etc. The structure and properties of biosimilars cannot be completely equivalent to the original drugs. The R&D cost of biosimilars is much higher than that of chemical generic drugs. Drug manufacturers need to verify the effectiveness and safety of drugs from the clinical research stage. Therefore, the biopharmaceutical industry has high financial and technical barriers.
After years of development, more than 20 recombinant protein drugs such as recombinant human insulin , interferon, interleukin, etc. have been launched. However, domestic companies mainly use imitation and R&D investment level is relatively low. Compared with developed countries, there is still a big gap in the overall technical level and innovation capabilities of my country's biopharmaceutical companies, especially in the fields of mammalian cell expression systems and monoclonal antibodies. In the future, the increase in R&D investment and the improvement of innovation capabilities of domestic enterprises will bring new opportunities to the development of the biopharmaceutical industry.
For more information, please refer to the "Research Report on Market Prospects and Investment Opportunities of China Biopharmaceutical Industry from 2020 to 2025" released by China Business Industry Research Institute. At the same time, China Business Industry Research Institute also provides solutions such as industrial big data, industrial planning and planning, industrial park planning, and industrial investment promotion.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-